Ubs Group Ag Unicycive Therapeutics, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding UNCY
# of Institutions
31Shares Held
46.8MCall Options Held
0Put Options Held
0-
Octagon Capital Advisors LP New York, NY8.56MShares$5.91 Million0.85% of portfolio
-
Great Point Partners LLC Greenwich, CT8.56MShares$5.91 Million1.62% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$3.5 Million0.28% of portfolio
-
Walleye Capital LLC Plymouth, MN5MShares$3.45 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.47MShares$3.08 Million0.27% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $10.4M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...